ACINETOCLINIC
31 Jul 14
ACINETOCLINIC Transition to Clinical Investigation Phase for Licencing of the First Vaccine Against Drug Resistent Acinetobacter Baumannii ABSTRACT Vaccines against
ACINETOCLINIC Transition to Clinical Investigation Phase for Licencing of the First Vaccine Against Drug Resistent Acinetobacter Baumannii ABSTRACT Vaccines against
IDP4MM Development of drugs in new therapeutic IDP targets for the treatment of multiple myeloma ABSTRACT This project is part
TOXAB Development of Novel, Safe and Affordable Cytotoxic Antibodies for the Treatment of Cancer ABSTRACT The main objective of the
NUEVAS DIANAS Discovery and combination of new treatments for cancer treatment based on the modulation of epigenetic targets and adenosine
MICROALMABS Validation of a New Platform for Production of Therapeutic Monoclonal Antibodies with Microalgae ABSTRACT The objective of the present
METASTASIS Anti-tumor and anti-metastasis activity of monoclonal antibodies in animal models of human cancers ABSTRACT The limited effectiveness of approved
LEITAT Attends IMI Stakeholder Forum 2014 in Brussels LEITAT is attending the IMI Stakeholder Forum 2014 in Brussels. The IMI
LEITAT, as a member of VISION2020, was presented during the H2020 Information Session dedicated to entrepreneurs. The meeting was hosted
The 24 Month progress meeting of RESTORATION EU Consortium was hosted by JRI Orthopaedics in Sheffield – UK. The Consortium
The Innovative Medicines Initiative (IMI) enters its second phase with a €3.3 billion budget and the ambitious goal of fast-tracking
This year’s the Annual Event of ETP-Nanomedicine is hosted by CIC NanoGUNE, the Spanish nano science cooperative research centre in
Researchers from BIOMED Division at LEITAT Technological Center, in collaboration with the University of Barcelona, demonstrated the efficacy of a
Horizon 2020, the EU’s new programme for investment in research and innovation, is expected to dedicate more than 7 billion
Boosting Health Sector to reduce its environmental impact using an innovative decision-making process based on LCA/LCC
Integration of Novel NANOparticle based technology for THERapeutics and diagnosi of different types of cancer.
Phone. (+34) 937 882 300
